TRANSGENE: E50.7 Million in Cash and Cash Equivalents as of March 31, 2017

information fournie par Boursorama •25/04/2017 à 18:00

E50.7 Million in Cash and Cash Equivalents as of March 31, 2017

•3 new clinical trials launched since the beginning of 2017
•New clinical collaboration with Bristol-Myers Squibb to evaluate
a TG4010 combination as first-line treatment in lung cancer
•Cash burn in line with expectations


Strasbourg, France, April 25, 2017, 6:00 p.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops viral-based immunotherapies, today announces its business update for the quarter ending March 31, 2017.
.../...

During the first quarter of 2017, revenue from collaborative and licensing agreements was mainly composed of research services and royalties.

As of March 31, 2017, government financing for research expenditures mainly consisted of 25% of the research tax credit expected for 2017 (E1.6 million in the first quarter of 2017, same as 2016).